EA201290158A1 - Композиция и способ лечения диабета - Google Patents
Композиция и способ лечения диабетаInfo
- Publication number
- EA201290158A1 EA201290158A1 EA201290158A EA201290158A EA201290158A1 EA 201290158 A1 EA201290158 A1 EA 201290158A1 EA 201290158 A EA201290158 A EA 201290158A EA 201290158 A EA201290158 A EA 201290158A EA 201290158 A1 EA201290158 A1 EA 201290158A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diabetes
- composition
- treatment
- acid
- buproprion
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 abstract 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 abstract 1
- 239000000859 incretin Substances 0.000 abstract 1
- 210000002429 large intestine Anatomy 0.000 abstract 1
- 150000004668 long chain fatty acids Chemical class 0.000 abstract 1
- 229940126403 monoamine reuptake inhibitor Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к способу лечения заболевания, связанного с инкретином, такого как диабет, ожирение и другие, путем доставки масляной кислоты, желчной кислоты, длинноцепочечной жирной кислоты или глутамина в толстый кишечник, минуя верхние отделы пищеварительного тракта. Указанную композицию комбинируют, вводя либо тем же, либо отличным путем, с ингибитором обратного захвата моноамина, таким как бупроприон.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24503609P | 2009-09-23 | 2009-09-23 | |
| PCT/US2010/049843 WO2011038014A2 (en) | 2009-09-23 | 2010-09-22 | Composition and method for treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201290158A1 true EA201290158A1 (ru) | 2012-08-30 |
Family
ID=43796466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201290158A EA201290158A1 (ru) | 2009-09-23 | 2010-09-22 | Композиция и способ лечения диабета |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9301938B2 (ru) |
| EP (1) | EP2480246A4 (ru) |
| JP (1) | JP2013505936A (ru) |
| KR (1) | KR20120082003A (ru) |
| CN (1) | CN102711800A (ru) |
| AU (1) | AU2010298303A1 (ru) |
| BR (1) | BR112012006437A2 (ru) |
| CA (1) | CA2774616A1 (ru) |
| CL (1) | CL2012000713A1 (ru) |
| EA (1) | EA201290158A1 (ru) |
| IN (1) | IN2012DN03257A (ru) |
| MX (1) | MX2012003459A (ru) |
| WO (1) | WO2011038014A2 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2364161B1 (en) * | 2008-11-26 | 2020-03-11 | Satiogen Pharmaceuticals, Inc. | Compositions containing satiogens and methods of use |
| EP2782588B1 (en) * | 2011-11-21 | 2020-04-15 | Emmaus Medical, Inc. | Methods and compositions for the treatment of diabetes and related symptoms |
| US20150073057A1 (en) * | 2013-09-06 | 2015-03-12 | Biokier, Inc. | Composition and method for treatment of diabetes |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| JP7136807B2 (ja) | 2017-04-17 | 2022-09-13 | ザ・ユニバーシティ・オブ・シカゴ | ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料 |
| WO2019165309A1 (en) | 2018-02-23 | 2019-08-29 | Ambra Bioscience Llc | Compositions and methods for hunger control and weight management |
| US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| US20200262887A1 (en) | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
| US20210267919A1 (en) * | 2020-02-28 | 2021-09-02 | Biokier, Inc. | Stabilized coated butyrate for colon release |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1245890B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
| PT1003476E (pt) | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
| US6652882B1 (en) | 1997-10-06 | 2003-11-25 | Intellipharmaceutics Corp | Controlled release formulation containing bupropion |
| GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
| DK1183014T3 (da) | 1999-06-14 | 2004-02-09 | Cosmo Spa | Smagsmaskerede orale farmaceutiske sammensætninger med kontrolleret frigivelse |
| WO2002022151A2 (en) * | 2000-09-18 | 2002-03-21 | Osteometer Bio Tech A/S | Use of glp-1 and flp-2 peptides for treatment of bone disorders |
| JP4141258B2 (ja) * | 2001-02-26 | 2008-08-27 | キッセイ薬品工業株式会社 | グルコピラノシルオキシピラゾール誘導体及びその医薬用途 |
| US20030203004A1 (en) | 2002-04-24 | 2003-10-30 | Kelm Gary Robert | Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight |
| US20040122033A1 (en) | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
| EP1506963B1 (en) | 2003-10-28 | 2005-04-13 | Adorkem Technology SpA | Method for the preparation of citalopram |
| ITMI20040187A1 (it) | 2004-02-06 | 2004-05-06 | Cosmo Spa | Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali |
| JP2006006304A (ja) | 2004-06-24 | 2006-01-12 | Emiko Nanri | 犬のフン受取器 |
| ITMI20041295A1 (it) | 2004-06-25 | 2004-09-25 | Cosmo Spa | Composizioni farmaceutiche antimicrobiche orali |
| JP2006056881A (ja) | 2004-07-21 | 2006-03-02 | Takeda Chem Ind Ltd | 縮合環化合物 |
| EP1884513A4 (en) | 2005-05-23 | 2010-04-28 | Japan Tobacco Inc | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME |
| DE102005046237A1 (de) | 2005-09-28 | 2007-04-05 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen |
| ITMI20052000A1 (it) | 2005-10-21 | 2007-04-22 | Promefarm S R L | Compressa gastroresitente a base di butirrato di sodio |
| ATE517086T1 (de) | 2005-11-30 | 2011-08-15 | Hoffmann La Roche | Verfahren zur synthese von 3-amino-1- arylpropylindolen |
| AU2007243131A1 (en) | 2006-01-20 | 2007-11-08 | Smithkline Beecham Corporation | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system |
| WO2008067219A2 (en) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| JP5580050B2 (ja) | 2006-12-15 | 2014-08-27 | ティーマ ファウンデーション | 組成物およびその使用 |
| US9339480B2 (en) | 2008-11-26 | 2016-05-17 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| EP2364161B1 (en) | 2008-11-26 | 2020-03-11 | Satiogen Pharmaceuticals, Inc. | Compositions containing satiogens and methods of use |
| EP2596786B1 (en) | 2009-02-10 | 2019-11-27 | Amarin Pharmaceuticals Ireland Limited | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
| LT3318255T (lt) | 2009-06-15 | 2021-05-25 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija |
| CA2775339C (en) | 2009-09-23 | 2017-03-28 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
-
2010
- 2010-09-22 MX MX2012003459A patent/MX2012003459A/es not_active Application Discontinuation
- 2010-09-22 EP EP20100819399 patent/EP2480246A4/en not_active Withdrawn
- 2010-09-22 EA EA201290158A patent/EA201290158A1/ru unknown
- 2010-09-22 BR BR112012006437A patent/BR112012006437A2/pt not_active Application Discontinuation
- 2010-09-22 AU AU2010298303A patent/AU2010298303A1/en not_active Abandoned
- 2010-09-22 JP JP2012530996A patent/JP2013505936A/ja active Pending
- 2010-09-22 KR KR1020127009900A patent/KR20120082003A/ko not_active Application Discontinuation
- 2010-09-22 CN CN2010800530328A patent/CN102711800A/zh active Pending
- 2010-09-22 WO PCT/US2010/049843 patent/WO2011038014A2/en active Application Filing
- 2010-09-22 US US13/497,114 patent/US9301938B2/en active Active
- 2010-09-22 CA CA2774616A patent/CA2774616A1/en not_active Abandoned
-
2012
- 2012-03-22 CL CL2012000713A patent/CL2012000713A1/es unknown
- 2012-04-16 IN IN3257DEN2012 patent/IN2012DN03257A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010298303A1 (en) | 2012-04-12 |
| JP2013505936A (ja) | 2013-02-21 |
| IN2012DN03257A (ru) | 2015-10-23 |
| MX2012003459A (es) | 2012-05-22 |
| WO2011038014A2 (en) | 2011-03-31 |
| CA2774616A1 (en) | 2011-03-31 |
| EP2480246A4 (en) | 2013-02-27 |
| US20120183617A1 (en) | 2012-07-19 |
| US9301938B2 (en) | 2016-04-05 |
| CN102711800A (zh) | 2012-10-03 |
| EP2480246A2 (en) | 2012-08-01 |
| KR20120082003A (ko) | 2012-07-20 |
| WO2011038014A3 (en) | 2011-08-11 |
| CL2012000713A1 (es) | 2012-08-10 |
| BR112012006437A2 (pt) | 2016-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290158A1 (ru) | Композиция и способ лечения диабета | |
| EA201190068A1 (ru) | Композиция и способ лечения диабета | |
| EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
| EA200700851A1 (ru) | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения | |
| EA201370208A1 (ru) | Формы рифаксимина и их применение | |
| MX2014005433A (es) | Métodos y composiciones para modular bacterias gastrointestinales para promover la salud. | |
| EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
| EA201290549A1 (ru) | Пептидный аналог оксинтомодулина | |
| EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
| GB2465879B (en) | Bile acid recylcing inhibitors for treatment of obesity and diabetes | |
| EA200970337A1 (ru) | Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения | |
| WO2011075539A3 (en) | Treatment of obesity or diabetes with bile acid sequestrants | |
| EA201000559A1 (ru) | Композиции и способы применения антител к склеростину | |
| EA201200977A1 (ru) | Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами | |
| EA201290557A1 (ru) | Пептидный аналог оксинтомодулина | |
| MX356584B (es) | Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica. | |
| EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
| EA201391454A1 (ru) | Композиция и способ лечения диабета | |
| EA201070039A1 (ru) | Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1 | |
| MX2011011768A (es) | Composiciones y metodos de uso para moleculas de enlace a dickkopf-1 o dickkopf-4 o a ambos. | |
| EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
| EA201200046A1 (ru) | Новые соединения, фармацевтическая композиция и связанные с ними способы | |
| ATE521358T1 (de) | Vorbeugender und/oder therapeutischer wirkstoff zur behandlung einer funktionellen gastrointestinalen erkrankung | |
| EA201000391A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
| EA201001749A1 (ru) | Способ лечения недифференцированного артрита |